EMAIL THIS PAGE TO A FRIEND

Drug metabolism and disposition: the biological fate of chemicals

Systemic exposure to and disposition of catechols derived from Salvia miltiorrhiza roots (Danshen) after intravenous dosing DanHong injection in human subjects, rats, and dogs.


PMID 25670806

Abstract

DanHong injection is a Danshen (Salvia miltiorrhiza roots)-based injectable solution for treatment of coronary artery disease and ischemic stroke. Danshen catechols are believed to be responsible for the injection's therapeutic effects. This study aimed to characterize systemic exposure to and elimination of Danshen catechols in human subjects, rats, and dogs receiving intravenous DanHong injection. A total of 28 catechols were detected, with content levels of 0.002-7.066 mM in the injection, and the major compounds included tanshinol, protocatechuic aldehyde, salvianolic acid B, rosmarinic acid, salvianolic acids A and D, and lithospermic acid with their daily doses ≥10 μmol/subject. After dosing, tanshinol, salvianolic acid D, and lithospermic acid exhibited considerable exposure in human subjects and rats. However, only tanshinol had considerable exposure in dogs. The considerable exposure to tanshinol was due to its having the highest dose, whereas that to salvianolic acid D and lithospermic acid was due to their relatively long elimination half-lives in the human subjects and rats. Protocatechuic aldehyde and rosmarinic acid circulated in the bloodstream predominantly as metabolites; salvianolic acids A and B exhibited low plasma levels with their human plasma metabolites little or not detected. Tanshinol and salvianolic acid D were eliminated mainly via renal excretion. Elimination of other catechols involved hepatobiliary and/or renal excretion of their metabolites. Methylation was found to be the primary metabolism for most Danshen catechols and showed intercompound and interspecies differences in rate and degree in vitro. The information gained here is relevant to pharmacological and toxicological research on DanHong injection.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

135011
1,2-Dihydroxybenzene, ReagentPlus®, ≥99%
C6H6O2
37580
3,4-Dihydroxybenzoic acid, ≥97.0% (T)
C7H6O4
08992
3,4-Dihydroxybenzoic acid, analytical standard
C7H6O4
143685
3-Hydroxy-4-methoxybenzaldehyde, 99%
C8H8O3
H4530
7-Hydroxyflavone, ≥98%
C15H10O3
C0625
Caffeic acid, ≥98.0% (HPLC)
C9H8O4
60018
Caffeic acid, matrix substance for MALDI-MS, ≥99.0% (HPLC)
C9H8O4
60020
Caffeic acid, purum, ≥95.0% (HPLC)
C9H8O4
C80105
Chrysin, 97%
C15H10O4
95082
Chrysin, analytical standard
C15H10O4
59940
Isovanillin, ≥95.0%
C8H8O3
03930590
Protocatechuic acid, primary pharmaceutical reference standard
C7H6O4
C9510
Pyrocatechol, ≥99%
C6H6O2
C3561
Pyrocatechol, plant cell culture tested, BioReagent, ≥99%, powder
C6H6O2
430749
Pyrocatechol, purified by sublimation, ≥99.5%
C6H6O2
536954
Rosmarinic acid, 96%
C18H16O8
00390580
Rosmarinic acid, primary pharmaceutical reference standard
C18H16O8
R4033
Rosmarinic acid, ≥98% (HPLC), from Rosemarinus officinalis L.
C18H16O8
Y0000786
Rosmarinic acid, European Pharmacopoeia (EP) Reference Standard
C18H16O8
04577
Trizma® base, tested according to Ph.Eur.
C4H11NO3
93440
Trizma® base, certified reference material for titrimetry, certified by BAM, according to ISO 17025, ≥99.5%
C4H11NO3
T2550000
Trometamol, European Pharmacopoeia (EP) Reference Standard
C4H11NO3
PHR1347
Tromethamine, Pharmaceutical Secondary Standard; Certified Reference Material
C4H11NO3
1698002
Tromethamine, United States Pharmacopeia (USP) Reference Standard
C4H11NO3
U3750
Uridine, ≥99%
C9H12N2O6
U3003
Uridine, powder, BioReagent, suitable for cell culture
C9H12N2O6
U6381
Uridine, BioUltra, ≥99%
C9H12N2O6
94770
Vanillic acid, purum, ≥97.0% (HPLC)
C8H8O4
H36001
Vanillic acid, 97%
C8H8O4
W398802
Vanillic acid, ≥97%, FG
C8H8O4